Finnish drug maker Biohit Oyj will reportedly launch patent drug Acetuim that could control blastomogen acetaldehyde, which is oriented to the Chinese market, revealed the CEO of the company Semi Korpela.
Biohit Oyj is currently registering the drug in China. Semi Korpela believed that Chinese locals are more likely to have gastric cancer because of genetic mutation and eating habits.
Source:
http://www.sinocast.com/readbeatarticle.do?id=93402
